The Year of Innovation and investment
Weleda Annual and Sustainability Report 2025
Weleda achieves record turnover through investment in the brand and its people
A comprehensive modernisation programme paves the way for further profitable growth.
Weleda AG, the global market leader in certified natural cosmetics and anthroposophic medicines, continued its growth trajectory in the 2025 financial year. The past financial year was characterised by innovation and investment in Weled’s sustainable and successful future. Revenue rose to €484.6 million (previous year: €456.2 million) – the highest figure in the company’s history.
The operating profit of €9.5 million (previous year: €23 million) was influenced by disproportionately high investment in brand modernisation and the successful launch of new products on the one hand, and a weaker pharmaceuticals business on the other.
Business year 2025
484.6
401.9
82.7
+ 6.2 %
+ 9.2 %
- 6.3 %
Record turnover for the second year running
In the 2025 financial year, we consistently advanced the comprehensive modernisation of Weleda and invested in the highest quality and future viability. It was a year of innovation and investment — in the brand, digitalisation, and additional specialist expertise. In doing so, we achieved a record turnover for the second consecutive year, whilst simultaneously laying the foundation for further profitable growth. Our substantial investments, particularly in the launch of new products, have driven our growth whilst having a short-term impact on our results.
„Our innovation offensive is paying off. We have never launched so many products successfully to market as in the past year, and every single one has contributed to growth.”
− Tina Müller, Chief Executive Officer - Weleda
Annual and Sustainability Report 2025
Financial year 2025: Weleda achieves record turnover through investment in its brand and people.
Weleda AG, the global market leader in certified natural cosmetics and anthroposophic medicines, continued its growth trajectory in the 2025 financial year. Revenue rose by 6.2% (7.3% exchange rate adjusted) to €484.6 million (previous year: €456.2 million) – the highest figure in the company’s history.
Strong performance in the Cosmetics Business Unit
Growth was driven by the strong performance of the Cosmetics Business Unit, which accounts for more than 80 % of total turnover.
In the cosmetics sector, we have grown faster than the market in a highly competitive environment. Particularly in our core region of D-A-CH, we gained significant market share with double-digit turnover growth — our new Weleda fans span every age group. The share of innovations in turnover in the DACH market stood at 32.8 per cent.
Most successful launch in the skincare segment
The new Booster Drops generated particularly strong demand amongst younger target groups — Generation Z above all. In Germany, the Booster Drops were the most successful product launch of the year in the skincare segment. We intend to further develop our Gen Z strategy and bring innovative products to market that keep Weleda contemporary and relevant across generations.
Weleda redefines natural skincare
We identified a clear customer need: that for highly effective certified natural cosmetics. With Cell Longevity, we are meeting this need: the latest science combined with our expertise of over 100 years enables Weleda to unlock the full power of nature - delivering our most potent and effective products to date. With the skincare range Cell Longevity and the multi-generational line minLen, we have entered the premium segment. Please note that Cell Longevity and minLen are not currently available in the UK.
Foundations for future growth in the Pharmaceuticals Business
Focused on a clearly defined range of Anthroposophic Medicines and R&D activities
In the Pharmaceuticals Business Unit, by contrast, Weleda was unable to match the prior year's level in a challenging market environment. Business development was impacted by structural changes in the bricks-and-mortar pharmacy market in Germany and an overall weaker demand in the homoeopathic and anthroposophic segment.
Important foundations have been laid for future growth in the pharmaceuticals business. Here, we are focusing on a clearly defined range of anthroposophic medicines centred on the therapeutic areas of eyes, stress and sleep, and digestion, whilst further expanding our R&D activities. These include important clinical and preclinical studies on the products Cardiodoron and Amara, with the aim of substantiating the scientific evidence.
Furthermore, we reorganised the sales and marketing activities in the pharmaceuticals division. These areas have been overseen since March 2026 by Dr Stefanie Haefele (left), who serves as Co-CPO (Chief Pharma Officer) alongside Co-CPO Dr Mónica Mennet-von Eiff (right), jointly leading the Pharmaceuticals Business Unit in a dual leadership structure.
Environmental figures Sustainability 2025
97 %
81 %
77 %
97 %
We show how sustainability makes an Impact
At Weleda Sustainability is built on a strategy with four fields of action
For us, sustainability is part of our identity. Our purpose commits us to taking responsibility consistently and to further developing sustainability as the foundation for our long-term economic future. With a clear strategy, Weleda makes sustainability visible and advances the company in a responsible manner. These four fields of action enable us to approach sustainability holistically, embed it systemically, and align our measures with targeted impact:
- Sustainable Products and Innovation
- Environmental Impact
- Responsible Supply Chains and Biodiversity
- Employees and Diversity
At Weleda, we uphold the highest quality standards along the entire value chain, from the cultivation of plants through to the finished product. We have done so for over 100 years, and our customers feel the difference. This is because the perception of quality also encompasses the sustainability of a product, as well as the aesthetics and design of the packaging. We have continued to invest in sustainability and have improved and consolidated key metrics at a high level.
Responsibility takes root
Our agricultural Management develops long-term projects for Critical and Strategic Raw Materials
Together with farmers and partners, we are transitioning to sustainable cultivation methods, thereby also fostering positive social impact at the source of our raw materials. In Tanzania, around 700 smallholder farmers are currently participating in the sesame project, which provides them and their families with an additional source of income. In France, a new composting system is strengthening soil fertility in rosemary cultivation. Our arnica also grows on an organic farm near Flensburg, Germany, where young plants, previously raised by a specialist nursery, made a strong start in the field. And in Morocco, the women's cooperative involved in rose cultivation benefits from a childcare facility and a health programme.
„For me, sustainability means taking responsibility where it truly makes a difference — for people, nature, and the future of the company.”
− Nadine-Hélène Santiago, Chief Sustainability Officer - Weleda